Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Heilongjiang ZBD Pharmaceutical Co Ltd (603567) - Total Liabilities
Latest total liabilities as of September 2025: CN¥4.51 Billion CNY
Based on the latest financial reports, Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has total liabilities worth CN¥4.51 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Heilongjiang ZBD Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Heilongjiang ZBD Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Heilongjiang ZBD Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MEC Company Ltd.
PINK:MECGF
|
USA | $5.48 Billion |
|
Dingli Communications Corp Ltd
SHE:300050
|
China | CN¥193.36 Million |
|
Enjoyor
SHE:300020
|
China | CN¥2.42 Billion |
|
CellaVision AB (publ)
PINK:CLVSF
|
USA | $207.31 Million |
|
Fine Organic Industries Limited
NSE:FINEORG
|
India | ₹1.83 Billion |
|
Myriad Genetics Inc
NASDAQ:MYGN
|
USA | $338.60 Million |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
China | CN¥1.10 Billion |
|
Stratasys Ltd
NASDAQ:SSYS
|
USA | $230.86 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Heilongjiang ZBD Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Heilongjiang ZBD Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total liabilities of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥4.42 Billion | -0.08% |
| 2023-12-31 | CN¥4.43 Billion | -3.14% |
| 2022-12-31 | CN¥4.57 Billion | +2.55% |
| 2021-12-31 | CN¥4.45 Billion | -5.84% |
| 2020-12-31 | CN¥4.73 Billion | +25.55% |
| 2019-12-31 | CN¥3.77 Billion | +17.81% |
| 2018-12-31 | CN¥3.20 Billion | +44.94% |
| 2017-12-31 | CN¥2.21 Billion | +4.48% |
| 2016-12-31 | CN¥2.11 Billion | +7.33% |
| 2015-12-31 | CN¥1.97 Billion | +37.49% |
| 2014-12-31 | CN¥1.43 Billion | -4.83% |
| 2013-12-31 | CN¥1.50 Billion | +86.07% |
| 2012-12-31 | CN¥808.30 Million | +56.43% |
| 2011-12-31 | CN¥516.70 Million | -- |